<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37298342</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Interstitial Lung Disease in Systemic Lupus Erythematosus and Systemic Sclerosis: How Can We Manage the Challenge?</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">9388</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms24119388</ELocationID><Abstract><AbstractText>Interstitial lung disease (ILD) is a severe and frequent manifestation of connective tissue diseases (CTD). Due to its debilitating potential, it requires serious evaluation and treatment. The prevalence of ILD in systemic lupus erythematosus (SLE) is still controversial. Therefore, in order to establish the diagnosis of ILD, an overlap syndrome must be excluded. Increasing the identification of SLE-associated ILD cases should become a target. To treat this complication, various therapies are now being proposed. To date, no placebo-controlled studies were conducted. Regarding another CTD, systemic sclerosis (SSc), SSc-associated ILD is considered one of the leading causes of mortality. The incidence of ILD varies among disease subtypes, being influenced by diagnostic method, but also by disease duration. Due to the high prevalence of this complication, all SSc patients should be investigated for ILD at the time of SSc diagnosis and during the course of the disease. Fortunately, progress was made in terms of treatment. Nintedanib, a tyrosine kinases inhibitor, showed promising results. It appeared to decrease the rate of progression of ILD compared to placebo. This review aimed to provide up-to-date findings related to SLE-associated ILD and SSc-associated ILD, in order to raise awareness of their diagnosis and management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cardoneanu</LastName><ForeName>Anca</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9800-9289</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dima</LastName><ForeName>Nicoleta</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Sf. Spiridon" Clinical Emergency Hospital, 700111 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bratoiu</LastName><ForeName>Ioana</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-2784-0937</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezus</LastName><ForeName>Ciprian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Sf. Spiridon" Clinical Emergency Hospital, 700111 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burlui</LastName><ForeName>Alexandra Maria</ForeName><Initials>AM</Initials><Identifier Source="ORCID">0000-0001-7361-4685</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costin</LastName><ForeName>Damiana</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macovei</LastName><ForeName>Luana Andreea</ForeName><Initials>LA</Initials><Identifier Source="ORCID">0000-0002-4856-867X</Identifier><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rezus</LastName><ForeName>Elena</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, "Grigore T Popa" University of Medicine and Pharmacy, 700115 Iasi, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Rehabilitation Hospital, 700661 Iasi, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="Y">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">interstitial lung disease</Keyword><Keyword MajorTopicYN="N">nintedanib</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">systemic sclerosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>15</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>10</Day><Hour>1</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37298342</ArticleId><ArticleId IdType="pmc">PMC10253395</ArticleId><ArticleId IdType="doi">10.3390/ijms24119388</ArticleId><ArticleId IdType="pii">ijms24119388</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tselios K., Urowitz M.B. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr. Rheumatol. Rev. 2017;13:206&#x2013;218. doi: 10.2174/1573397113666170704102444.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573397113666170704102444</ArticleId><ArticleId IdType="pubmed">28675998</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee C.T., Strek M.E. The Other Connective Tissue Disease-Associated Interstitial Lung Diseases: Sjogren&#x2019;s Syndrome, Mixed Connective Tissue Disease, and Systemic Lupus Erythematosus. Curr. Opin. Pulm. Med. 2021;27:388&#x2013;395. doi: 10.1097/MCP.0000000000000791.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MCP.0000000000000791</ArticleId><ArticleId IdType="pmc">PMC8373683</ArticleId><ArticleId IdType="pubmed">34127620</ArticleId></ArticleIdList></Reference><Reference><Citation>Cotton T., Fritzler M.J., Choi M.Y., Zheng B., Niaki O.Z., Pineau C.A., Lukusa L., Bernatsky S. Serologic Phenotypes Distinguish Systemic Lupus Erythematosus Patients Developing Interstitial Lung Disease and/or Myositis. Lupus. 2022;31:1477&#x2013;1484. doi: 10.1177/09612033221122158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221122158</ArticleId><ArticleId IdType="pmc">PMC9580032</ArticleId><ArticleId IdType="pubmed">36018314</ArticleId></ArticleIdList></Reference><Reference><Citation>Mittoo S., Fischer A., Strand V., Meehan R., Swigris J.J. Systemic Lupus Erythematosus-Related Interstitial Lung Disease. Curr. Rheumatol. Rev. 2010;6:99&#x2013;107. doi: 10.2174/157339710791330759.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/157339710791330759</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilera-Pickens G., Abud-Mendoza C. Pulmonary Manifestations in Systemic Lupus Erythematosus: Pleural Involvement, Acute Pneumonitis, Chronic Interstitial Lung Disease and Diffuse Alveolar Hemorrhage. Reumatol. Clin. (Engl. Ed.) 2018;14:294&#x2013;300. doi: 10.1016/j.reuma.2018.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.reuma.2018.03.012</ArticleId><ArticleId IdType="pubmed">29773465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallianos K. Imaging of Pulmonary Manifestations of Connective Tissue Disease. Radiol. Clin. N. Am. 2022;60:915&#x2013;924. doi: 10.1016/j.rcl.2022.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcl.2022.06.003</ArticleId><ArticleId IdType="pubmed">36202478</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaseer S., James J.A., Thanou A., Merrill J.T. Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody. ACR Meet. Abstr. 2014;66:S308&#x2013;S309.</Citation></Reference><Reference><Citation>Narv&#xe1;ez J., Borrell H., S&#xe1;nchez-Alonso F., R&#xfa;a-Figueroa I., L&#xf3;pez-Longo F.J., Galindo-Izquierdo M., Calvo-Al&#xe9;n J., Fern&#xe1;ndez-Nebro A., Oliv&#xe9; A., Andreu J.L., et al. Primary Respiratory Disease in Patients with Systemic Lupus Erythematosus: Data from the Spanish Rheumatology Society Lupus Registry (RELESSER) Cohort. Arthritis Res. Ther. 2018;20:280. doi: 10.1186/s13075-018-1776-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-018-1776-8</ArticleId><ArticleId IdType="pmc">PMC6299951</ArticleId><ArticleId IdType="pubmed">30567600</ArticleId></ArticleIdList></Reference><Reference><Citation>Amarnani R., Yeoh S.-A., Denneny E.K., Wincup C. Lupus and the Lungs: The Assessment and Management of Pulmonary Manifestations of Systemic Lupus Erythematosus. Front. Med. 2020;7:610257. doi: 10.3389/fmed.2020.610257.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.610257</ArticleId><ArticleId IdType="pmc">PMC7847931</ArticleId><ArticleId IdType="pubmed">33537331</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuchacovich R., Gedalia A. Pathophysiology and Clinical Spectrum of Infections in Systemic Lupus Erythematosus. Rheum Dis. Clin. N. Am. 2009;35:75&#x2013;93. doi: 10.1016/j.rdc.2009.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.03.003</ArticleId><ArticleId IdType="pubmed">19480998</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathai S.C., Danoff S.K. Management of Interstitial Lung Disease Associated with Connective Tissue Disease. BMJ. 2016;352:h6819. doi: 10.1136/bmj.h6819.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.h6819</ArticleId><ArticleId IdType="pmc">PMC6887350</ArticleId><ArticleId IdType="pubmed">26912511</ArticleId></ArticleIdList></Reference><Reference><Citation>Enomoto N., Egashira R., Tabata K., Hashisako M., Kitani M., Waseda Y., Ishizuka T., Watanabe S., Kasahara K., Izumi S., et al. Analysis of Systemic Lupus Erythematosus-Related Interstitial Pneumonia: A Retrospective Multicentre Study. Sci. Rep. 2019;9:7355. doi: 10.1038/s41598-019-43782-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-43782-7</ArticleId><ArticleId IdType="pmc">PMC6517420</ArticleId><ArticleId IdType="pubmed">31089189</ArticleId></ArticleIdList></Reference><Reference><Citation>Panagopoulos P., Goules A., Hoffmann-Vold A.M., Matteson E.L., Tzioufas A. Natural History and Screening of Interstitial Lung Disease in Systemic Autoimmune Rheumatic Disorders. Ther. Adv. Musculoskelet Dis. 2021;13:1759720X211037519. doi: 10.1177/1759720X211037519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X211037519</ArticleId><ArticleId IdType="pmc">PMC8404673</ArticleId><ArticleId IdType="pubmed">34471427</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J.I., Lee K.H., Park S., Yang J.W., Kim H.J., Song K., Lee S., Na H., Jang Y.J., Nam J.Y., et al. Systemic Lupus Erythematosus and Lung Involvement: A Comprehensive Review. J. Clin. Med. 2022;11:6714. doi: 10.3390/jcm11226714.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11226714</ArticleId><ArticleId IdType="pmc">PMC9698564</ArticleId><ArticleId IdType="pubmed">36431192</ArticleId></ArticleIdList></Reference><Reference><Citation>Qiu F., Li Y., Zhu Y., Li G., Lei F., Zhang S., Luo L., Zhu J., Guo Y., Du B., et al. CX3CR1 Might Be a Promising Predictor of Systemic Lupus Erythematosus Patients with Pulmonary Fibrosis. Scand. J. Immunol. 2021;94:e13038. doi: 10.1111/sji.13038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.13038</ArticleId><ArticleId IdType="pubmed">33665864</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielepkowicz-Go&#x17a;dzi&#x144;ska A., Fendler W., Robak E., Kulczycka-Siennicka L., G&#xf3;rski P., Pietras T., Brzezia&#x144;ska E., Pietrusi&#x144;ska M., Antczak A. The Role of CXC Chemokines in Pulmonary Fibrosis of Systemic Lupus Erythematosus Patients. Arch. Immunol. Ther. Exp. 2015;63:465&#x2013;473. doi: 10.1007/s00005-015-0356-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00005-015-0356-8</ArticleId><ArticleId IdType="pubmed">26275808</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Smolen J.S. Tumour Necrosis Factor and Other Proinflammatory Cytokines in Systemic Lupus Erythematosus: A Rationale for Therapeutic Intervention. Lupus. 2004;13:344&#x2013;347. doi: 10.1191/0961203303lu1024oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu1024oa</ArticleId><ArticleId IdType="pubmed">15230290</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Mutairi S., Al-Awadhi A., Raghupathy R., Al-Khawari H., Sada P., Al-Herz A., Rawoot P. Lupus Patients with Pulmonary Involvement Have a Pro-Inflammatory Cytokines Profile. Rheumatol. Int. 2007;27:621&#x2013;630. doi: 10.1007/s00296-006-0268-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-006-0268-3</ArticleId><ArticleId IdType="pubmed">17103171</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng K.-H., Chen D.-Y., Lin C.-H., Chao W.-C., Chen Y.-M., Chen Y.-H., Huang W.-N., Hsieh T.-Y., Lai K.-L., Tang K.-T., et al. Risk of Interstitial Lung Disease in Patients with Newly Diagnosed Systemic Autoimmune Rheumatic Disease: A Nationwide, Population-Based Cohort Study. Semin. Arthritis Rheum. 2020;50:840&#x2013;845. doi: 10.1016/j.semarthrit.2020.07.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2020.07.011</ArticleId><ArticleId IdType="pubmed">32896697</ArticleId></ArticleIdList></Reference><Reference><Citation>Toyoda Y., Koyama K., Kawano H., Nishimura H., Kagawa K., Morizumi S., Naito N., Sato S., Yamashita Y., Takahashi N., et al. Clinical Features of Interstitial Pneumonia Associated with Systemic Lupus Erythematosus. Respir. Investig. 2019;57:435&#x2013;443. doi: 10.1016/j.resinv.2019.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2019.04.005</ArticleId><ArticleId IdType="pubmed">31235450</ArticleId></ArticleIdList></Reference><Reference><Citation>Medlin J.L., Hansen K.E., McCoy S.S., Bartels C.M. Pulmonary Manifestations in Late versus Early Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Semin. Arthritis Rheum. 2018;48:198&#x2013;204. doi: 10.1016/j.semarthrit.2018.01.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2018.01.010</ArticleId><ArticleId IdType="pmc">PMC6067995</ArticleId><ArticleId IdType="pubmed">29550111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamen D.L., Strange C. Pulmonary Manifestations of Systemic Lupus Erythematosus. Clin. Chest Med. 2010;31:479&#x2013;488. doi: 10.1016/j.ccm.2010.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2010.05.001</ArticleId><ArticleId IdType="pubmed">20692540</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeleniewicz R., Suszek D., Majdan M. Clinical Picture of Late-Onset Systemic Lupus Erythematosus in a Group of Polish Patients. Pol. Arch. Med. Wewn. 2015;125:538&#x2013;544. doi: 10.20452/pamw.2963.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.2963</ArticleId><ArticleId IdType="pubmed">26075796</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertoli A.M., Vila L.M., Apte M., Fessler B.J., Bastian H.M., Reveille J.D., Alarcon G.S. Systemic Lupus Erythematosus in a Multiethnic US Cohort LUMINA XLVIII: Factors Predictive of Pulmonary Damage. Lupus. 2007;16:410&#x2013;417. doi: 10.1177/0961203307079042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203307079042</ArticleId><ArticleId IdType="pubmed">17664231</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisenberg H., Dubois E.L., Sherwin R.P., Balchum O.J. Diffuse Interstitial Lung Disease in Systemic Lupus Erythematosus. Ann. Intern. Med. 1973;79:37&#x2013;45. doi: 10.7326/0003-4819-79-1-37.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-79-1-37</ArticleId><ArticleId IdType="pubmed">4124484</ArticleId></ArticleIdList></Reference><Reference><Citation>ter Borg E.J., Groen H., Horst G., Limburg P.C., Wouda A.A., Kallenberg C.G. Clinical Associations of Antiribonucleoprotein Antibodies in Patients with Systemic Lupus Erythematosus. Semin. Arthritis Rheum. 1990;20:164&#x2013;173. doi: 10.1016/0049-0172(90)90057-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(90)90057-M</ArticleId><ArticleId IdType="pubmed">2287941</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward M.M., Polisson R.P. A Meta-Analysis of the Clinical Manifestations of Older-Onset Systemic Lupus Erythematosus. Arthritis Rheum. 1989;32:1226&#x2013;1232. doi: 10.1002/anr.1780321007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/anr.1780321007</ArticleId><ArticleId IdType="pubmed">2803325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Wang Y., Chen X., Liang H., Yang X. Association of Interstitial Lung Disease with Clinical Characteristics of Chinese Patients with Systemic Lupus Erythematosus. Arch. Rheumatol. 2020;35:239&#x2013;246. doi: 10.46497/ArchRheumatol.2020.7583.</Citation><ArticleIdList><ArticleId IdType="doi">10.46497/ArchRheumatol.2020.7583</ArticleId><ArticleId IdType="pmc">PMC7406170</ArticleId><ArticleId IdType="pubmed">32851373</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia F.F., Lu F.A., Lv H.M., Yang G.A., Liu Y. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia. Beijing Da Xue Xue Bao Yi Xue Ban. 2021;53:266&#x2013;272.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8072446</ArticleId><ArticleId IdType="pubmed">33879896</ArticleId></ArticleIdList></Reference><Reference><Citation>Frankel S.K., Brown K.K. Collagen Vascular Diseases of the Lung. Clin. Pulm. Med. 2006;13:25. doi: 10.1097/01.cpm.0000197403.64631.de.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.cpm.0000197403.64631.de</ArticleId></ArticleIdList></Reference><Reference><Citation>Min J.K., Hong Y.S., Park S.H., Park J.H., Lee S.H., Lee Y.S., Kim H.H., Cho C.S., Kim H.Y. Bronchiolitis Obliterans Organizing Pneumonia as an Initial Manifestation in Patients with Systemic Lupus Erythematosus. J. Rheumatol. 1997;24:2254&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pubmed">9375894</ArticleId></ArticleIdList></Reference><Reference><Citation>Tansey D., Wells A.U., Colby T.V., Ip S., Nikolakoupolou A., du Bois R.M., Hansell D.M., Nicholson A.G. Variations in Histological Patterns of Interstitial Pneumonia between Connective Tissue Disorders and Their Relationship to Prognosis. Histopathology. 2004;44:585&#x2013;596. doi: 10.1111/j.1365-2559.2004.01896.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2559.2004.01896.x</ArticleId><ArticleId IdType="pubmed">15186274</ArticleId></ArticleIdList></Reference><Reference><Citation>Yood R.A., Steigman D.M., Gill L.R. Lymphocytic Interstitial Pneumonitis in a Patient with Systemic Lupus Erythematosus. Lupus. 1995;4:161&#x2013;163. doi: 10.1177/096120339500400217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339500400217</ArticleId><ArticleId IdType="pubmed">7795624</ArticleId></ArticleIdList></Reference><Reference><Citation>Pego-Reigosa J.M., Medeiros D.A., Isenberg D.A. Respiratory Manifestations of Systemic Lupus Erythematosus: Old and New Concepts. Best. Pract. Res. Clin. Rheumatol. 2009;23:469&#x2013;480. doi: 10.1016/j.berh.2009.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.berh.2009.01.002</ArticleId><ArticleId IdType="pubmed">19591778</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheema G.S., Quismorio F.P. Interstitial Lung Disease in Systemic Lupus Erythematosus. Curr. Opin. Pulm. Med. 2000;6:424&#x2013;429. doi: 10.1097/00063198-200009000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00063198-200009000-00007</ArticleId><ArticleId IdType="pubmed">10958234</ArticleId></ArticleIdList></Reference><Reference><Citation>Paran D., Fireman E., Elkayam O. Pulmonary Disease in Systemic Lupus Erythematosus and the Antiphospholpid Syndrome. Autoimmun. Rev. 2004;3:70&#x2013;75. doi: 10.1016/S1568-9972(03)00090-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1568-9972(03)00090-9</ArticleId><ArticleId IdType="pubmed">14871652</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivero M., Padera R.F. Histopathology of Lung Disease in the Connective Tissue Diseases. Rheum. Dis. Clin. N. Am. 2015;41:197&#x2013;211. doi: 10.1016/j.rdc.2014.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2014.12.002</ArticleId><ArticleId IdType="pubmed">25836637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenlon H.M., Doran M., Sant S.M., Breatnach E. High-Resolution Chest CT in Systemic Lupus Erythematosus. AJR Am. J. Roentgenol. 1996;166:301&#x2013;307. doi: 10.2214/ajr.166.2.8553934.</Citation><ArticleIdList><ArticleId IdType="doi">10.2214/ajr.166.2.8553934</ArticleId><ArticleId IdType="pubmed">8553934</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan C.E., Reyes-Caballero K.S., Samson M.J.T., Lichauco J.J. TP33. TP033 CASE REPORTS IN AUTOIMMUNE LUNG DISEASE. American Thoracic Society; New York, NY, USA: 2021. Case of 54 Year-Old Patient with Systemic Lupus Erythematosus-Interstitial Lung Disease Managed with Intravenous Immunoglobulin; p. A2059.</Citation></Reference><Reference><Citation>Marcu D.T.M., Adam C.A., Mitu F., Cumpat C., Aursulesei Onofrei V., Zabara M.L., Burlacu A., Crisan Dabija R. Cardiovascular Involvement in Tuberculosis: From Pathophysiology to Diagnosis and Complications&#x2014;A Narrative Review. Diagnostics. 2023;13:432. doi: 10.3390/diagnostics13030432.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13030432</ArticleId><ArticleId IdType="pmc">PMC9914020</ArticleId><ArticleId IdType="pubmed">36766543</ArticleId></ArticleIdList></Reference><Reference><Citation>Hannah J.R., D&#x2019;Cruz D.P. Pulmonary Complications of Systemic Lupus Erythematosus. Semin. Respir. Crit. Care Med. 2019;40:227&#x2013;234. doi: 10.1055/s-0039-1685537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0039-1685537</ArticleId><ArticleId IdType="pubmed">31137062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lian F., Zhou J., Wang Y., Cui W., Chen D., Li H., Qiu Q., Zhan Z., Ye Y., Liang L., et al. Clinical Features and Independent Predictors of Interstitial Lung Disease in Systemic Lupus Erythematosus. Int. J. Clin. Exp. Med. 2016;9:4233&#x2013;4242.</Citation></Reference><Reference><Citation>Di Bartolomeo S., Alunno A., Carubbi F. Respiratory Manifestations in Systemic Lupus Erythematosus. Pharmaceuticals. 2021;14:276. doi: 10.3390/ph14030276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14030276</ArticleId><ArticleId IdType="pmc">PMC8003168</ArticleId><ArticleId IdType="pubmed">33803847</ArticleId></ArticleIdList></Reference><Reference><Citation>White C.S. Interstitial Pulmonary Fibrosis in Systemic Lupus Erythematosus: Are There Variants of the Variant Fibrotic Patterns? Radiol. Cardiothorac. Imaging. 2021;3:e210183. doi: 10.1148/ryct.2021210183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/ryct.2021210183</ArticleId><ArticleId IdType="pmc">PMC8415144</ArticleId><ArticleId IdType="pubmed">34498011</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre O., Harari S. Pleural and Pulmonary Involvement in Systemic Lupus Erythematosus. Presse. Med. 2011;40:e19&#x2013;e29. doi: 10.1016/j.lpm.2010.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lpm.2010.11.004</ArticleId><ArticleId IdType="pubmed">21194884</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmucci S., Galioto F., Fazio G., Ferlito A., Cancemi G., Di Mari A., Sambataro G., Sambataro D., Zanframundo G., Mauro L.A., et al. Clinical and Radiological Features of Lung Disorders Related to Connective-Tissue Diseases: A Pictorial Essay. Insights Imaging. 2022;13:108. doi: 10.1186/s13244-022-01243-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13244-022-01243-2</ArticleId><ArticleId IdType="pmc">PMC9243214</ArticleId><ArticleId IdType="pubmed">35767157</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanouriakis A., Kostopoulou M., Alunno A., Aringer M., Bajema I., Boletis J.N., Cervera R., Doria A., Gordon C., Govoni M., et al. 2019 Update of the EULAR Recommendations for the Management of Systemic Lupus Erythematosus. Ann. Rheum. Dis. 2019;78:736&#x2013;745. doi: 10.1136/annrheumdis-2019-215089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215089</ArticleId><ArticleId IdType="pubmed">30926722</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorthi R., Attoti Y., Atluri R., Mwangi J.K. D38. CASE REPORTS IN AUTOIMMUNE LUNG DISEASE. American Thoracic Society; New York, NY, USA: 2020. Belimumab in the Treatment of Interstitial Lung Disease Associated with Systemic Lupus Erythematosus; p. 6643. American Thoracic Society International Conference Abstracts.</Citation></Reference><Reference><Citation>Kokosi M., Lams B., Agarwal S. Systemic Lupus Erythematosus and Antiphospholipid Antibody Syndrome. Clin. Chest Med. 2019;40:519&#x2013;529. doi: 10.1016/j.ccm.2019.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccm.2019.06.001</ArticleId><ArticleId IdType="pubmed">31376888</ArticleId></ArticleIdList></Reference><Reference><Citation>Vacchi C., Sebastiani M., Cassone G., Cerri S., Della Casa G., Salvarani C., Manfredi A. Therapeutic Options for the Treatment of Interstitial Lung Disease Related to Connective Tissue Diseases. A Narrative Review. J. Clin. Med. 2020;9:407. doi: 10.3390/jcm9020407.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9020407</ArticleId><ArticleId IdType="pmc">PMC7073957</ArticleId><ArticleId IdType="pubmed">32028635</ArticleId></ArticleIdList></Reference><Reference><Citation>Muangchan C., van Vollenhoven R.F., Bernatsky S.R., Smith C.D., Hudson M., Inan&#xe7; M., Rothfield N.F., Nash P.T., Furie R.A., Sen&#xe9;cal J.-L., et al. Treatment Algorithms in Systemic Lupus Erythematosus. Arthritis Care Res. 2015;67:1237&#x2013;1245. doi: 10.1002/acr.22589.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.22589</ArticleId><ArticleId IdType="pubmed">25777803</ArticleId></ArticleIdList></Reference><Reference><Citation>Koo S.-M., Uh S.-T. Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: The Pulmonologist&#x2019;s Point of View. Korean J. Intern. Med. 2017;32:600&#x2013;610. doi: 10.3904/kjim.2016.212.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.2016.212</ArticleId><ArticleId IdType="pmc">PMC5511941</ArticleId><ArticleId IdType="pubmed">28704913</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinrib L., Sharma O.P., Quismorio F.P. A Long-Term Study of Interstitial Lung Disease in Systemic Lupus Erythematosus. Semin. Arthritis Rheum. 1990;20:48&#x2013;56. doi: 10.1016/0049-0172(90)90094-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-0172(90)90094-V</ArticleId><ArticleId IdType="pubmed">2218553</ArticleId></ArticleIdList></Reference><Reference><Citation>Mwangi J., Litteken C., Gorthi R., Attoti Y., Atluri R., Mwangi J., Litteken C., Gorthi R., Attoti Y., Atluri R. Belimumab in the Treatment of Connective Tissue Disease-Associated Interstitial Lung Disease: Case Report and Literature Review. Cureus. 2021;13:e19218. doi: 10.7759/cureus.19218.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.19218</ArticleId><ArticleId IdType="pmc">PMC8639321</ArticleId><ArticleId IdType="pubmed">34873544</ArticleId></ArticleIdList></Reference><Reference><Citation>Keir G.J., Maher T.M., Ming D., Abdullah R., de Lauretis A., Wickremasinghe M., Nicholson A.G., Hansell D.M., Wells A.U., Renzoni E.A. Rituximab in Severe, Treatment-Refractory Interstitial Lung Disease. Respirology. 2014;19:353&#x2013;359. doi: 10.1111/resp.12214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/resp.12214</ArticleId><ArticleId IdType="pubmed">24286447</ArticleId></ArticleIdList></Reference><Reference><Citation>Robles-Perez A., Dorca J., Castellv&#xed; I., Nolla J.M., Molina-Molina M., Narv&#xe1;ez J. Rituximab Effect in Severe Progressive Connective Tissue Disease-Related Lung Disease: Preliminary Data. Rheumatol. Int. 2020;40:719&#x2013;726. doi: 10.1007/s00296-020-04545-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-020-04545-0</ArticleId><ArticleId IdType="pubmed">32157369</ArticleId></ArticleIdList></Reference><Reference><Citation>Eiser A.R., Shanies H.M. Treatment of Lupus Interstitial Lung Disease with Intravenous Cyclophosphamide. Arthritis Rheum. 1994;37:428&#x2013;431. doi: 10.1002/art.1780370318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780370318</ArticleId><ArticleId IdType="pubmed">8129799</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink S.D., Kremer J.M. Successful Treatment of Interstitial Lung Disease in Systemic Lupus Erythematosus with Methotrexate. J. Rheumatol. 1995;22:967&#x2013;969.</Citation><ArticleIdList><ArticleId IdType="pubmed">8587090</ArticleId></ArticleIdList></Reference><Reference><Citation>Swigris J.J., Olson A.L., Fischer A., Lynch D.A., Cosgrove G.P., Frankel S.K., Meehan R.T., Brown K.K. Mycophenolate Mofetil Is Safe, Well Tolerated, and Preserves Lung Function in Patients with Connective Tissue Disease-Related Interstitial Lung Disease. Chest. 2006;130:30&#x2013;36. doi: 10.1016/S0012-3692(15)50949-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0012-3692(15)50949-5</ArticleId><ArticleId IdType="pubmed">16840379</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim S.W., Gillis D., Smith W., Hissaria P., Greville H., Peh C.A. Rituximab Use in Systemic Lupus Erythematosus Pneumonitis and a Review of Current Reports. Intern. Med. J. 2006;36:260&#x2013;262. doi: 10.1111/j.1445-5994.2006.01055.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1445-5994.2006.01055.x</ArticleId><ArticleId IdType="pubmed">16640745</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M., Suzuki K., Matsumoto M., Nakashima M., Nakanishi T., Takada K., Horikoshi H., Matsubara O., Ohsuzu F. Intermittent Intravenous Cyclophosphamide Pulse Therapy for the Treatment of Active Interstitial Lung Disease Associated with Collagen Vascular Diseases. Mod. Rheumatol. 2007;17:131&#x2013;136. doi: 10.3109/s10165-007-0554-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/s10165-007-0554-2</ArticleId><ArticleId IdType="pubmed">17437168</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumida H., Asano Y., Tamaki Z., Aozasa N., Taniguchi T., Takahashi T., Toyama T., Ichimura Y., Noda S., Akamata K., et al. Successful Experience of Rituximab Therapy for Systemic Sclerosis-Associated Interstitial Lung Disease with Concomitant Systemic Lupus Erythematosus. J. Dermatol. 2014;41:418&#x2013;420. doi: 10.1111/1346-8138.12461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1346-8138.12461</ArticleId><ArticleId IdType="pubmed">24801917</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang B.-B., Man X.-Y., Zheng M. Pirfenidone Combined with Corticosteroids in a Patient with Systemic Lupus Erythematosus-Associated Interstitial Lung Disease. J. Eur. Acad. Dermatol. Venereol. 2017;31:e388&#x2013;e389. doi: 10.1111/jdv.14192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jdv.14192</ArticleId><ArticleId IdType="pubmed">28261880</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawata M., Nagayasu A., Fujita Y., Nawata A., Saito K., Tanaka Y. Severe Pulmonary Arterial Hypertension and Interstitial Pneumonia Related to Systemic Lupus Erythematosus Successfully Treated with Mycophenolate Mofetil: A Novel Case Report. Lupus. 2020;29:1955&#x2013;1960. doi: 10.1177/0961203320958055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320958055</ArticleId><ArticleId IdType="pubmed">32914681</ArticleId></ArticleIdList></Reference><Reference><Citation>Perelas A., Silver R., Arrossi A., Highland K. Systemic sclerosis-associated interstitial lung disease. Lancet Respir. Med. 2020;8:304&#x2013;320. doi: 10.1016/S2213-2600(19)30480-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(19)30480-1</ArticleId><ArticleId IdType="pubmed">32113575</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna D., Tashkin D., Denton C., Renzoni E., Desai S., Varga J. Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. Am. J. Respir. Crit. Care Med. 2020;201:650&#x2013;660. doi: 10.1164/rccm.201903-0563CI.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201903-0563CI</ArticleId><ArticleId IdType="pmc">PMC7068837</ArticleId><ArticleId IdType="pubmed">31841044</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihtyanova S., Denton C. Pathogenesis of Systemic Sclerosis Associated Interstitial Lung Disease. J. Scleroderma Relat. Disord. 2020;5((Suppl. S2)):6&#x2013;16. doi: 10.1177/2397198320903867.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2397198320903867</ArticleId><ArticleId IdType="pmc">PMC8922569</ArticleId><ArticleId IdType="pubmed">35382227</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker M., Graf N., Sauter R., Allanore Y., Curram J., Denton C., Khanna D., Matucci-Cerinic M., de Oliveira Pena J., Pope J., et al. Predictors of disease worsening defined by progression of organ damage in diffuse systemic sclerosis: A European Scleroderma Trials and Research (EUSTAR) analysis. Ann. Rheum. Dis. 2019;78:1242&#x2013;1248. doi: 10.1136/annrheumdis-2019-215145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2019-215145</ArticleId><ArticleId IdType="pmc">PMC6788922</ArticleId><ArticleId IdType="pubmed">31227488</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu W., Jordan S., Graf N., de Oliveira Pena J., Curram J., Allanore Y., Matucci-Cerinic M., Denton C., Khanna D. Progressive Skin Fibrosis Is Associated with a Decline in Lung Function and Worse Survival in Patients with Diffuse Cutaneous Systemic Sclerosis in the European Scleroderma Trials and Research (EUSTAR) Cohort. Ann. Rheum. Dis. 2019;78:648&#x2013;656. doi: 10.1136/annrheumdis-2018-213455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2018-213455</ArticleId><ArticleId IdType="pmc">PMC6517861</ArticleId><ArticleId IdType="pubmed">30852552</ArticleId></ArticleIdList></Reference><Reference><Citation>Nihtyanova S., Schreiber B., Ong V., Rosenberg D., Moinzadeh P., Coghlan J.G., Wells A.U., Denton C.P. Prediction of Pulmonary Complications and Long-Term Survival in Systemic Sclerosis. Arthritis Rheumatol. 2014;66:1625&#x2013;1635. doi: 10.1002/art.38390.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.38390</ArticleId><ArticleId IdType="pubmed">24591477</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann-Vold A.M., Maher T.M., Philpot E.E., Ashrafzadeh A., Barake R., Barsotti S., Bruni C., Carducci P., Carreira P.E., Castellvi I., et al. The Identification and Management of Interstitial Lung Disease in Systemic Sclerosis: Evidence-based European Consensus Statements. Lancet Rheumatol. 2020;2:e71&#x2013;e83. doi: 10.1016/S2665-9913(19)30144-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30144-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann-Vold A.M., Molberg &#xd8;. Detection, Screening, and Classification of Interstitial Lung Disease in Patients with Systemic Sclerosis. Curr. Opin. Rheumatol. 2020;32:497&#x2013;500. doi: 10.1097/BOR.0000000000000741.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000741</ArticleId><ArticleId IdType="pubmed">32890027</ArticleId></ArticleIdList></Reference><Reference><Citation>Chung J., Walker C.M., Hobbs S.B. Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease. J. Vis. Exp. 2020;160:e60300.</Citation><ArticleIdList><ArticleId IdType="pubmed">32744514</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebata S., Yoshizaki-Ogawa A., Sato S., Yoshizaki A. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics. J. Clin. Med. 2022;11:4631. doi: 10.3390/jcm11154631.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11154631</ArticleId><ArticleId IdType="pmc">PMC9369903</ArticleId><ArticleId IdType="pubmed">35956246</ArticleId></ArticleIdList></Reference><Reference><Citation>Roofeh D., Lescoat A., Khanna D. Treatment for systemic sclerosis-associated interstitial lung disease. Curr. Opin. Rheumatol. 2021;33:240&#x2013;248. doi: 10.1097/BOR.0000000000000795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000795</ArticleId><ArticleId IdType="pmc">PMC8021460</ArticleId><ArticleId IdType="pubmed">33741803</ArticleId></ArticleIdList></Reference><Reference><Citation>Vonk M., Smith V., Sfikakis P., Cutolo M., Del Galdo F., Seibold J. Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmun. Rev. 2021;20:102978. doi: 10.1016/j.autrev.2021.102978.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102978</ArticleId><ArticleId IdType="pubmed">34718159</ArticleId></ArticleIdList></Reference><Reference><Citation>Richeldi L., du Bois R., Raghu G., Azuma A., Brown K., Costabel U., Cottin V., Flaherty K., Hansell D., Inoue Y., et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014;370:2071&#x2013;2082. doi: 10.1056/NEJMoa1402584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1402584</ArticleId><ArticleId IdType="pubmed">24836310</ArticleId></ArticleIdList></Reference><Reference><Citation>Wollin L., Maillet I., Quesniaux V., Holweg A., Ryffel B. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J. Pharmacol. Exp. Ther. 2014;349:209&#x2013;220. doi: 10.1124/jpet.113.208223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.113.208223</ArticleId><ArticleId IdType="pubmed">24556663</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutolo M., Gotelli E., Montagna P., Tardito S., Paolino S., Pizzorni C., Sulli A., Smith V., Soldano S. Nintedanib downregulates the transition of cultured systemic sclerosis fibrocytes into myofibroblasts and their pro-fibrotic activity. Arthritis Res. Ther. 2021;23:205. doi: 10.1186/s13075-021-02555-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02555-2</ArticleId><ArticleId IdType="pmc">PMC8330043</ArticleId><ArticleId IdType="pubmed">34344444</ArticleId></ArticleIdList></Reference><Reference><Citation>Distler O., Highland K., Gahlemann M., Azuma A., Fischer A., Mayes M., Raghu G., Sauter W., Girard M., Alves M., et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N. Engl. J. Med. 2019;380:2518&#x2013;2528. doi: 10.1056/NEJMoa1903076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1903076</ArticleId><ArticleId IdType="pubmed">31112379</ArticleId></ArticleIdList></Reference><Reference><Citation>Flaherty K.R., Wells A.U., Cottin V., Devaraj A., Walsh S.L.F., Inoue Y., Richeldi L., Kolb M., Tetzlaff K., Stowasser S., et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N. Engl. J. Med. 2019;381:1718&#x2013;1727. doi: 10.1056/NEJMoa1908681.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1908681</ArticleId><ArticleId IdType="pubmed">31566307</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwana M., Ogura T., Makino S., Homma S., Kondoh Y., Saito A., Ugai H., Gahlemann M., Takehara K., Azuma A. Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Mod. Rheumatol. 2020;31:141&#x2013;150. doi: 10.1080/14397595.2020.1751402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2020.1751402</ArticleId><ArticleId IdType="pubmed">32243207</ArticleId></ArticleIdList></Reference><Reference><Citation>Seibold J., Maher T., Highland K., Assassi S., Azuma A., Hummers L., Costabel U., von Wangenheim U., Kohlbrenner V., Gahlemann M., et al. Safety and tolerability of nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from the SENSCIS trial. Ann. Rheum. Dis. 2020;79:1478&#x2013;1484. doi: 10.1136/annrheumdis-2020-217331.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-217331</ArticleId><ArticleId IdType="pmc">PMC7569371</ArticleId><ArticleId IdType="pubmed">32759258</ArticleId></ArticleIdList></Reference><Reference><Citation>Azuma A., Chung L., Behera D., Chung M., Kondoh Y., Ogura T., Okamoto M., Swarnakar R., Zeng X., Zou H., et al. Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial. Respir. Investig. 2021;59:252&#x2013;259. doi: 10.1016/j.resinv.2020.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.resinv.2020.10.005</ArticleId><ArticleId IdType="pubmed">33223487</ArticleId></ArticleIdList></Reference><Reference><Citation>Highland K., Distler O., Kuwana M., Allanore Y., Assassi S., Azuma A., Bourdin A., Denton C., Distler J., Hoffmann-Vold A., et al. Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: A subgroup analysis of the SENSCIS trial. Lancet Respir. Med. 2021;9:96&#x2013;106. doi: 10.1016/S2213-2600(20)30330-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30330-1</ArticleId><ArticleId IdType="pubmed">33412120</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher T., Mayes M., Kreuter M., Volkmann E., Aringer M., Castellvi I., Cutolo M., Stock C., Schoof N., Alves M., et al. ffect of Nintedanib on Lung Function in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Further Analyses of a Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2021;73:671&#x2013;676. doi: 10.1002/art.41576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41576</ArticleId><ArticleId IdType="pmc">PMC8048624</ArticleId><ArticleId IdType="pubmed">33142016</ArticleId></ArticleIdList></Reference><Reference><Citation>Allanore Y., Vonk M., Distler O., Azuma A., Mayes M., Gahlemann M., James A., Kohlbrenner V., Alves M., Khanna D., et al. Continued treatment with nintedanib in patients with systemic sclerosis-associated interstitial lung disease: Data from SENSCIS-ON. Ann. Rheum. Dis. 2022;81:1722&#x2013;1729. doi: 10.1136/ard-2022-222564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard-2022-222564</ArticleId><ArticleId IdType="pmc">PMC9664126</ArticleId><ArticleId IdType="pubmed">35973804</ArticleId></ArticleIdList></Reference><Reference><Citation>Assassi S., Distler O., Allanore Y., Ogura T., Varga J., Vettori S., Crestani B., Voss F., Alves M., Stowasser S., et al. Effect of Nintedanib on Progression of Systemic Sclerosis-Associated Interstitial Lung Disease Over 100&#x2009;Weeks: Data From a Randomized Controlled Trial. ACR Open Rheumatol. 2022;4:837&#x2013;844. doi: 10.1002/acr2.11483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr2.11483</ArticleId><ArticleId IdType="pmc">PMC9555199</ArticleId><ArticleId IdType="pubmed">35852465</ArticleId></ArticleIdList></Reference><Reference><Citation>Denton C., Goh N., Humphries S., Maher T., Spiera R., Devaraj A., Ho L., Stock C., Erhardt E., Alves M., et al. Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: Data from the SENSCIS trial. Rheumatology. 2022;62:1870&#x2013;1876. doi: 10.1093/rheumatology/keac535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac535</ArticleId><ArticleId IdType="pmc">PMC10152288</ArticleId><ArticleId IdType="pubmed">36111858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter M., Hoffmann-Vold A., Matucci-Cerinic M., LA S., Highland K., Wilson H., Alves M., Erhardt E., Schoof N., Maher T. Impact of lung function and baseline clinical characteristics on patient-reported outcome measures in systemic sclerosis-associated interstitial lung disease. Rheumatology. 2022;62:S143&#x2013;S153. doi: 10.1093/rheumatology/keac325.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac325</ArticleId><ArticleId IdType="pmc">PMC9910566</ArticleId><ArticleId IdType="pubmed">35640959</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreuter M., Del Galdo F., Miede C., Khanna D., Wuyts W., Hummers L., Alves M., Schoof N., Stock C., Allanore Y. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): A joint model analysis. Arthritis Res. Ther. 2022;24:19. doi: 10.1186/s13075-021-02710-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13075-021-02710-9</ArticleId><ArticleId IdType="pmc">PMC8751320</ArticleId><ArticleId IdType="pubmed">35012623</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuwana M., Allanore Y., Denton C., Distler J., Steen V., Khanna D., Matucci-Cerinic M., Mayes M., Volkmann E., Miede C., et al. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis Rheumatol. 2022;74:518&#x2013;526. doi: 10.1002/art.41965.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41965</ArticleId><ArticleId IdType="pmc">PMC9306495</ArticleId><ArticleId IdType="pubmed">34514739</ArticleId></ArticleIdList></Reference><Reference><Citation>Maher T., Bourdin A., Volkmann E., Vettori S., Distler J., Alves M., Stock C., Distler O. Decline in forced vital capacity in subjects with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial compared with healthy reference subjects. Respir. Res. 2022;23:178. doi: 10.1186/s12931-022-02095-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12931-022-02095-6</ArticleId><ArticleId IdType="pmc">PMC9258095</ArticleId><ArticleId IdType="pubmed">35790961</ArticleId></ArticleIdList></Reference><Reference><Citation>Volkmann E., Kreuter M., Hoffmann-Vold A., Wijsenbeek M., Smith V., Khanna D., Denton C., Wuyts W., Miede C., Alves M., et al. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial. Rheumatology. 2022;61:4397&#x2013;4408. doi: 10.1093/rheumatology/keac091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keac091</ArticleId><ArticleId IdType="pmc">PMC9629379</ArticleId><ArticleId IdType="pubmed">35150246</ArticleId></ArticleIdList></Reference><Reference><Citation>Konopka K.E., Myers J.L. Interstitial lung disease pathology in systemic sclerosis. Ther. Adv. Musculoskelet. Dis. 2021;13:1759720X211032437. doi: 10.1177/1759720X211032437.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1759720X211032437</ArticleId><ArticleId IdType="pmc">PMC8287363</ArticleId><ArticleId IdType="pubmed">34349846</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>